Marwa Aly | Bacterial Extracellular Vesicles | Best Researcher Award

Published on by Cell Biologist

Dr. Marwa Aly | Bacterial Extracellular Vesicles | Best Researcher Award

Dr. Marwa Aly | HB Fuller | United States

Dr. Marwa Aly (published as Marwa Gamal Saad), Ph.D., is a Senior Scientist at H.B. Fuller Company with an impressive interdisciplinary background spanning microbiology, bioengineering, nanotechnology, and biotechnology. She holds dual Ph.D. degrees from Port Said University (with research at Texas A&M University) and Washington State University, where she recently completed a thesis on bacterial extracellular vesicles targeting drug-resistant pathogens. Dr. Aly has authored multiple high-impact publications, secured substantial research funding, and contributed to patent-pending technologies. Her innovative work bridges the gap between microbial research and real-world applications, such as alternative biofuels and novel antimicrobials. With an h-index of 6 and over 250 citations, she has demonstrated consistent scientific impact. Recognized by prestigious awards like the Cougar Cage Award and WSU President’s Leadership Award, Dr. Aly is an emerging thought leader in microbial biotechnology, making her a prime candidate for the Best Researcher Award.

Publication Profiles:

Google Scholar
Scopus
Orcid

Education:

Dr. Marwa Aly holds two Doctor of Philosophy degrees in advanced scientific disciplines. She earned her first Ph.D. in Botany from Port Said University, Egypt, with collaborative research at Texas A&M University, USA. Her research focused on sustainable biofuel production from microalgae using nanotechnology and genetic engineering. She recently completed a second Ph.D. in Engineering from Washington State University, USA. Her dissertation investigated bacterial extracellular vesicles and their potential as next-generation antimicrobials against drug-resistant pathogens. Dr. Aly’s dual doctoral qualifications reflect her interdisciplinary expertise and commitment to solving complex global challenges. Her educational journey is marked by innovation, academic rigor, and successful translation of research into real-world impact.

Research Experience:

As a Graduate Assistant at Washington State University in Dr. Wen-Ji Dong’s Lab, Dr. Aly has pioneered research on microbial extracellular vesicles (EVs), securing a provisional patent and winning $100,000 in Cougar Cage funding. Her work involves in vitro and in vivo analysis of EVs from Pseudomonas aeruginosa, exploring their antimicrobial action, especially against Candida auris and drug-resistant pathogens. She also studies the role of ferroptosis in EV-mediated treatment strategies and has led proteomic profiling of bacterial biofilms. In her earlier Ph.D. work, she developed methods for microalgae-based biodiesel production using advanced microfluidics and nanotechnology. Her multidisciplinary research blends microbiology, chemical engineering, and biotechnology to address critical challenges in public health and sustainable energy. Her scientific contributions are recognized globally, making her a strong contender for research excellence.

Awards and Honors:

Dr. Marwa Aly has received multiple prestigious accolades recognizing her leadership, innovation, and research excellence. She was a winner of the ISEV Image Competition, celebrating creativity in extracellular vesicle research. She received the Cougar Cage Award from Washington State University for her promising EV-based antimicrobial proposal. Her leadership and academic excellence earned her the WSU President’s Award for Leadership and recognition as a WSU Woman of Distinction. These awards highlight not only her scientific contributions but also her dedication to community engagement, mentorship, and cross-disciplinary collaboration. Her ability to secure competitive funding, publish impactful research, and innovate at the intersection of biology and engineering underscores her qualifications for the Best Researcher Award.

Research Focus:

Dr. Marwa Aly’s research centers on extracellular vesicles (EVs) and their potential to combat antimicrobial resistance. Her recent focus is on stage-dependent EVs produced by Pseudomonas aeruginosa and algae, exploring their ability to disrupt biofilms and trigger ferroptosis in pathogenic organisms. Her research includes proteomic analysis, biofilm interaction studies, and in vivo wound infection models, advancing the understanding of EVs as therapeutic agents. Additionally, she has conducted microfluidic-based studies for biofuel optimization, developing innovative devices to study microalgae growth under various environmental conditions. Her work is grounded in translational science, bridging lab discoveries with industrial applications such as bioenergy and infection control. By integrating microbiology, bioengineering, and nanotech, she is at the forefront of next-generation biotechnologies, making substantial contributions to public health, sustainability, and microbial sciences.

Publications Top Notes:

  1. Algal Biofuels: Current Status and Key Challenges – Energies

  2. Exosomes as Powerful Engines in Cancer: Isolation, Characterization and Detection Techniques – Biosensors

  3. Evaluation of Storage Stability for Biocrude Derived from Hydrothermal Liquefaction of Microalgae – Energy & Fuels

  4. High-Throughput Screening of Chlorella Vulgaris Growth Kinetics in Microfluidics – Biomolecules

  5. Droplet-based Microfluidic Gradient for Chlorella Growth under Nitrogen & Temp Stress – Algal Research

  6. Impact of Nitrogen Regime on Fatty Acid Profiles of Algae for Biofuel – Acta Botanica Hungarica

  7. Dual Roles of Conditional Extracellular Vesicles from Pseudomonas Biofilms – Biofilm

  8. Phytochemical Screening and Antimicrobial Activity of Egyptian Green Algae – Journal of Medicinal Plants Studies

  9. Nitrogen Concentration Impact on Algal Biomass, Lipids & Biofuel Yield – IJSTR

  10. Challenges of Biodiesel Production from Oscillatoria sp. – IJAR

Conclusion:

In conclusion, Dr. Marwa Aly (Marwa Gamal Saad) is a highly qualified, driven, and impactful researcher who has made significant contributions across several vital scientific areas, from microbial therapeutics to renewable biofuels. Her dual-Ph.D. credentials, publication record, patent-pending research, competitive grant success, and multiple recognitions make her an excellent candidate for the Best Researcher Award. While she can further enhance her profile through increased international engagement and publication output, her current achievements already distinguish her as a rising leader in the fields of biotechnology, microbiology, and bioengineering. She is not only suitable but highly recommended for this recognition.

Lei Shi | Tumorigenesis | Distinguished Scientist Award

Published on by Cell Biologist

Mr. Lei Shi | Tumorigenesis | Distinguished Scientist Award

Mr. Lei Shi, Lanzhou University, China

Dr. Lei Shi is a distinguished cancer biologist and molecular pathologist, currently serving as a Professor and Group Leader at the School of Public Health, Lanzhou University, China. With an international career spanning Germany, the UK, and China, Dr. Shi has significantly contributed to our understanding of long non-coding RNAs (lncRNAs), KRAS-mediated tumorigenesis, and lung cancer biology. He earned his Ph.D. from Ludwig Maximilian University of Munich, and completed postdoctoral training at the CRUK Manchester Institute, one of the world’s premier cancer research centers. His interdisciplinary research bridges cancer signaling, immunotherapy, and molecular genetics. Dr. Shi has been the recipient of multiple national and international grants and has authored numerous high-impact publications in journals such as Nature Communications, Molecular Cancer, and Cell Death & Differentiation. His research plays a pivotal role in advancing personalized cancer therapy and diagnostics, making him a strong contender for the Distinguished Scientist Award.

Publication Profile: 

Orcid

Scopus

Strengths for the Award:

  1. Extensive Expertise in Tumorigenesis
    Dr. Shi has built a deep and consistent research track record in lung cancer biology, KRAS signaling, and non-coding RNAs—critical areas in modern tumorigenesis research. His work spans oncogene-driven pathways, epigenetics, and RNA biology, which are all highly relevant to the theme of this award.

  2. Strong International Training and Collaborations
    His academic path includes a Ph.D. in Germany (LMU Munich), a postdoctoral fellowship in the UK (University of Manchester/Cancer Research UK), and leadership in China—demonstrating international impact and collaboration.

  3. Proven Research Leadership
    As a Group Leader and Professor at Lanzhou University, Dr. Shi has led grants from both national and provincial Chinese funding bodies, showcasing strong institutional leadership and research independence.

  4. High-Impact Publications
    Dr. Shi has multiple first-author and corresponding-author publications in top-tier journals like Nature Communications, Molecular Cancer, Cell Death & Differentiation, Cancer Research, and others. This indicates a sustained contribution to scientific knowledge with measurable impact.

  5. Focus on Translational Relevance
    His work on KRAS-mediated tumorigenesis, lncRNAs in cancer, microRNA regulation, and drug resistance directly contributes to potential cancer therapies and diagnostics, aligning with the translational emphasis of many distinguished awards.

  6. Mentorship and Emerging Talent Development
    Multiple publications list junior co-authors under his supervision, showing that he actively mentors young scientists and builds collaborative research teams.

Areas for Improvement:

  1. Broader Recognition in Global Awards
    While Dr. Shi has an impressive research footprint, there is limited mention of international awards, editorial roles, or keynote presentations, which are often considered markers of distinguished global leadership.

  2. Clinical Translation or Patents
    The profile would benefit from stronger clinical application indicators, such as patents, clinical trials, or biotechnology translation, to further demonstrate real-world impact.

  3. Broader Research Diversification
    Although his expertise is deep in KRAS and RNA biology, engaging with emerging areas like AI in cancer research, organoid modeling, or immune-oncology interfaces could amplify his multidisciplinary influence.

Education:

Dr. Lei Shi’s academic journey is deeply rooted in life sciences and molecular pathology. He obtained his Bachelor’s degree in Veterinary Medicine (2003–2007) from Heibei North University, China, followed by a Master’s degree (2007–2010) in Agricultural Microbiology at Huazhong Agricultural University, where he developed his early interest in pathogenic mechanisms. He then pursued his Ph.D. (Dr.rer.nat) in Molecular Pathology (2011–2014) at the Ludwig Maximilian University of Munich, Germany, under the mentorship of Prof. Dr. Heiko Hermeking. His doctoral research explored the transcriptional regulation of tumor suppressors and oncogenes. This academic progression built a solid foundation in molecular oncology, leading to a postdoctoral fellowship (2015–2021) at the Cancer Research UK Manchester Institute and Lung Cancer Centre of Excellence, UK. Dr. Shi’s diverse education has provided him with a global and translational perspective on cancer biology, strengthening his leadership in molecular oncology research today.

Professional Experience:

Dr. Lei Shi is a Professor and Group Leader (2021–present) at Lanzhou University, where he heads translational cancer biology research within the School of Public Health. Prior to this, he held a prestigious Postdoctoral Research Fellow role (2015–2021) at the Cancer Research UK Manchester Institute, affiliated with The University of Manchester. There, he conducted cutting-edge research on KRAS-driven lung cancers, drug resistance mechanisms, and RNA therapeutics. Earlier, he was a Ph.D. researcher (2011–2014) at Ludwig Maximilian University of Munich, delving into the regulatory roles of p53 and lncRNAs. His professional experience reflects a continuum of cancer research from fundamental science to translational applications. Dr. Shi’s team at Lanzhou University is now exploring new therapeutic targets for non-small cell lung cancer and virus-associated cancers. He has secured multiple prestigious national and international grants and is actively mentoring the next generation of cancer researchers in China.

Research Focus:

Dr. Lei Shi’s research centers on the molecular mechanisms of cancer development and progression, with a primary focus on long non-coding RNAs (lncRNAs), KRAS oncogene signaling, and RNA-based therapeutic strategies. His lab investigates how lncRNAs modulate gene expression, interact with microRNAs, and influence tumor microenvironment and immune response, particularly in non-small cell lung cancer (NSCLC) and virus-related malignancies. Dr. Shi is also exploring transcriptional feedback loops, including interactions between HIF1A-AS2 and MYC, to unravel how oncogenic pathways fuel metastasis. His postdoctoral work revealed KRAS-induced microRNA regulation, significantly advancing the understanding of RNA biology in cancer. Dr. Shi’s research integrates bioinformatics, functional genomics, and clinical samples to identify novel biomarkers and therapeutic targets. His contributions are paving the way for precision oncology, making a significant impact on early diagnosis, patient stratification, and drug resistance profiling in solid tumors, especially lung cancer.

Publications Top Notes: 

  1. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy – Molecular Cancer (2025)

  2. Long non-coding RNA-encoded micropeptides: functions, mechanisms and implications – Cell Death & Discovery (2024)

  3. p53-regulated lncRNAs in cancers: from proliferation and metastasis to therapy – Cancer Gene Therapy (2023)

  4. Long non-coding RNA HIF1A-As2 and MYC form a double positive feedback loop in NSCLC – Cell Death & Differentiation (2023)

  5. Long non-coding RNAs in virus-related cancers – Reviews in Medical Virology (2022)

  6. Prognostic and immunotherapeutic roles of KRAS in Pan-Cancer – Cells (2022)

  7. A KRAS-responsive long non-coding RNA controls microRNA processing – Nature Communications (2021)

  8. Diverse roles of long non-coding RNA in viral diseases – Reviews in Medical Virology (2020)

  9. Vulnerability of drug-resistant EML4-ALK lung cancer to transcriptional inhibition – EMBO Mol Med (2020)

  10. KRAS induces lung tumorigenesis through microRNAs modulation – Cell Death & Disease (2018)

  11. The immunological and prognostic landscape of TFAP4 in cancer (scRNA-seq study) – Archives of Biochemistry and Biophysics (2025)

Conclusion:

Dr. Lei Shi is highly suitable for the Distinguished Scientist Award in Tumorigenesis Research. His exceptional publication record, international training, leadership in cancer biology, and dedication to translational science make him a standout candidate. With ongoing contributions and future expansion into cross-disciplinary domains, his research trajectory is aligned with the highest standards of scientific distinction.

Mohammad reza Atashzar | Cancer stem cell | Best Researcher Award

Published on by Cell Biologist

Dr. Mohammad reza Atashzar | Cancer stem cell | Best Researcher Award

Dr. Mohammad reza Atashzar, Dep of immunology, Fasa university of medical sciences ( FUMS ), Iran

Dr. Mohammad Reza Atashzar is an Assistant Professor in the Department of Immunology at Fasa University of Medical Sciences (FUMS), Iran. With an enduring passion for tumor immunology, stem cells, vaccine design, and immunotherapy, he has made significant contributions through both basic and translational research. Dr. Atashzar earned his PhD in Immunology from Shahid Beheshti University of Medical Sciences and has since engaged in teaching, mentoring, and publishing extensively in high-impact journals such as The Lancet Oncology, Frontiers in Immunology, and Current Molecular Medicine. His innovative research spans exosome-based therapy, cancer biomarkers, cytokine profiling, and radiogenomics. Dr. Atashzar has also contributed to international collaborations across Germany, Finland, and the UK, showcasing a global outlook in biomedical science. An awardee of the KAI 2022 International Travel Grant and recognized as the Top Researcher at FUMS in 2021, he remains deeply committed to advancing immunological sciences for clinical and therapeutic benefit.

Publication Profile: 

Orcid

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Dr. Atashzar has authored numerous peer-reviewed publications in reputable journals including The Lancet Oncology, Frontiers in Immunology, Current Molecular Medicine, and Computers in Biology and Medicine. His work spans critical fields like cancer immunology, exosome therapy, stem cell immunomodulation, and vaccine research.

  2. High-Impact Publications
    Several of his papers have significant citation counts—556 for Frontiers in Immunology, 284 for Journal of Cellular Physiology, and 207 for The Lancet Oncology, reflecting strong influence and relevance in the scientific community.

  3. International Recognition and Collaborations
    He has participated in international conferences (UK, China, Korea, Denmark, Spain, Italy) and collaborated with global institutions such as the University of Helsinki, University of Kiel, and GBD Collaborators, demonstrating a global research footprint.

  4. Innovation and Patents
    He has contributed to translational science through a published book on immunopharmacology and a pending patent for a microbiology loop sterilizer device, showing practical application of his research.

  5. Awards and Editorial Involvement
    Recognized with the International Travel Award (KAI 2022) and Top Researcher of FUMS (2021), and serving on editorial boards of scientific journals—further affirming his active role in academic development and peer review.

  6. Interdisciplinary Research Scope
    His research merges clinical immunology, oncology, AI-based prognostic tools, and cellular therapy, making his work not only innovative but also future-oriented.

⚠️ Areas for Improvement:

  1. Increase in First or Senior Author Publications
    While his contributions are numerous, strengthening his authorship role in key studies would amplify his recognition as a principal investigator.

  2. Patent Commercialization & Technology Transfer
    Moving from patent design to real-world implementation or licensing could significantly raise the translational value of his research.

  3. Higher Grant Involvement
    More participation in national/international grant-funded programs or consortiums would enhance the scale and visibility of his research.

  4. Focused Research Niche
    Narrowing focus slightly (e.g., prioritizing tumor immunology or exosome-based therapies) could help build a globally recognized brand in a specialized field.

🎓 Education:

Dr. Atashzar completed his undergraduate and master’s studies in Immunology at Shiraz University of Medical Sciences (SUMS), Shiraz, Iran. Building on his foundational expertise, he pursued his PhD in Immunology at Shahid Beheshti University of Medical Sciences, Tehran. His doctoral thesis—“Investigation of the Effects of B16F10 Derived Exosomes Enriched with miRNA-211 in Induction of Antitumor Response in the Mouse Model of Melanoma”—reflected his early interest in cancer immunotherapy and translational research. Throughout his academic journey, Dr. Atashzar displayed a strong inclination toward exploring novel immune pathways and cell-based therapies. His formal education has laid a robust foundation for his ongoing work in immunological sciences, particularly in relation to tumor microenvironment, cytokine profiling, exosomes, and vaccine innovation. He has also undertaken continuous learning through collaborations and international scientific conferences, allowing him to integrate cutting-edge methodologies into his research and teaching repertoire.

🧪 Professional Experience:

Dr. Mohammad Reza Atashzar currently serves as an Assistant Professor of Immunology at Fasa University of Medical Sciences, with additional teaching responsibilities at Larestan University of Medical Sciences. He has accumulated over a decade of experience in academic instruction and biomedical research. His research portfolio includes multiple funded projects, notably in cancer immunology, cytokine regulation, diabetes-related immune responses, and exosome-based therapeutics. Dr. Atashzar has worked closely with international teams in Germany, Finland, and the UK, facilitating interdisciplinary approaches and innovations in clinical immunology. He is an editorial board member for reputed journals such as The International Journal of Neuroscience and Journal of International Medical Research. In parallel, he actively contributes to conference presentations worldwide, covering topics from cancer stem cells to immune biomarkers. His hands-on laboratory experience, combined with a global research network, enables him to lead and mentor in advanced areas like CAR-T cell therapy and personalized immunotherapy.

🧬 Research Focus:

Dr. Atashzar’s research is centered on tumor immunology, exosome-based therapies, cancer stem cells, CAR-T cell technology, cytokine profiling, and immunopharmacology. He has a keen interest in how immune cells—particularly T cells, NK cells, and regulatory B cells—can be harnessed for cancer therapy. His notable projects have explored the immunomodulatory effects of miRNA-enriched exosomes, the role of TLR4 polymorphisms in diabetes, and cytokine alterations in addiction and radiation-exposed individuals. He is also pioneering in translational research areas such as vaccine design, radiogenomics, and bio-immune device development. Dr. Atashzar integrates bioinformatics and machine learning for predictive modeling, evident in his contributions to COVID-19 prognostic modeling using CT radiomics. His work is driven by the goal of personalized immunotherapy and the identification of novel biomarkers for cancer progression and immune regulation. Through interdisciplinary collaborations, he aims to bridge the gap between immunological research and clinical application.

📚 Publications Top Notes:

  1. 🧬 Cancer stem cells: A review from origin to therapeutic implications – Journal of Cellular Physiology

  2. 🧪 Tumor‐Derived Exosomes Enriched by miRNA‐211a Promote Antitumor Immune Response in B16F10 Tumor‐Bearing Mice – APMIS

  3. 🔬 The effects of tumor-derived exosomes enriched with miRNA-211a on B16F10 cells – Contemporary Oncology

  4. 💉 The effects of type 2 diabetes mellitus on organ metabolism and the immune system – Frontiers in Immunology

  5. 🧠 Pyrin and hematopoietic interferon-inducible nuclear protein domain proteins: innate immune sensors for cytosolic and nuclear DNA – Critical Reviews in Immunology

  6. 🧪 Reduced levels of T-helper 17-associated cytokines in serum of breast cancer patients – Central European Journal of Immunology

  7. 🧫 The Role of IL‐6, IL‐10 and CRP in Gastrointestinal Cancers – Cell Biology International

  8. 🌍 The global burden of adolescent and young adult cancer in 2019 – The Lancet Oncology

  9. 🖥️ COVID-19 prognostic modeling using CT radiomic features and ML algorithms – Computers in Biology and Medicine

  10. 🌡️ Mesenchymal stromal cells in bone marrow niche of multiple myeloma – Cancer Cell International

📌 Conclusion:

Dr. Mohammad Reza Atashzar is highly suitable for the Best Researcher Award. His body of work reflects a deep commitment to scientific advancement in cancer immunology, immunotherapy, and bio-innovation. He combines strong academic output with international engagement, cross-disciplinary impact, and teaching contributions. With growing influence in both research and translational domains, Dr. Atashzar is poised to further elevate biomedical research in Iran and globally.

Hongliang Xin | Tissue Engineering Regeneration | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Hongliang Xin | Tissue Engineering Regeneration | Best Researcher Award

Prof. Dr. Hongliang Xin, Nanjing Medical University, China

Professor Hongliang Xin is a distinguished pharmaceutical scientist at Nanjing Medical University, China. After earning his PhD from Fudan University in 2011, he joined Nanjing Medical University and rapidly rose through academic ranks, becoming a full professor by 2020. His international experience includes a research fellowship at North Carolina State University (2015–2016), enriching his global academic outlook. Professor Xin has made significant contributions in drug delivery, particularly for brain disorders and cancer. His work on biomimetic nanoparticles and dual-targeting systems has been widely recognized, with several of his publications cited hundreds of times. He is a recipient of the Jiangsu Outstanding Research Award and has contributed to translational science through interdisciplinary collaboration. Committed to innovation in intelligent drug delivery, Professor Xin continues to push boundaries in nanomedicine. His dedication and impactful research make him a strong candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Innovative Research in Drug Delivery
    Prof. Xin has led pioneering work in cellular biomimetic drug delivery systems and brain-targeted therapies, particularly utilizing Angiopep-conjugated and ROS-responsive nanoparticles. His research shows deep innovation in crossing the blood-brain barrier — a major challenge in neuroscience and oncology.

  2. Strong Publication Record
    He has authored multiple high-impact publications in top-tier journals such as Biomaterials, ACS Nano, and Advanced Materials. Several of these works have citations exceeding 300–400, indicating significant influence in the scientific community.

  3. International Research Exposure
    His experience as a visiting scholar at North Carolina State University reflects a global approach to science, enhancing both the breadth and depth of his research collaborations.

  4. Consistent Career Growth
    From lecturer to professor within a decade, Prof. Xin’s steady academic rise reflects both merit and dedication.

  5. Recognition and Awards
    Recipient of the Jiangsu Outstanding Research Award, validating his contributions at the provincial and national level.

⚙️ Areas for Improvement:

  1. Clinical Translation
    While preclinical research is robust, moving towards clinical trials or commercial partnerships would greatly strengthen the translational impact of his work.

  2. Leadership in International Consortia
    Increased participation or leadership in global research initiatives, conferences, or consortia could further elevate his visibility and impact internationally.

  3. Cross-Disciplinary Outreach
    Expanding collaborations into neuropsychology, regenerative medicine, or pharmaceutical industry applications could broaden the application of his delivery systems.

🎓 Education:

Hongliang Xin completed his doctoral studies in Pharmacy at Fudan University in 2011, one of China’s most prestigious universities. His academic journey was grounded in pharmaceutical sciences, focusing on drug delivery systems and nanotechnology-based therapies. During his PhD, he laid the foundation for his future research in targeted therapy and biomimetic materials. Post-PhD, he expanded his academic training internationally as a visiting scholar at North Carolina State University in the United States (2015–2016). This exposure to global research trends and interdisciplinary approaches further honed his expertise. The integration of chemical engineering, pharmacology, and nanotechnology into his educational training has allowed him to develop innovative and effective therapeutic strategies for brain-targeted drug delivery. His education has not only equipped him with strong technical skills but also with a visionary approach to translational medicine.

🧪 Experience:

Dr. Hongliang Xin began his academic career as a lecturer at Nanjing Medical University’s School of Pharmacy in 2011. He was promoted to Associate Professor in 2015 and became a Full Professor in 2020. Over the years, he has built a robust research program in nanomedicine and drug delivery, leading multiple funded projects and mentoring graduate students. His one-year tenure as a visiting scholar at North Carolina State University provided him international collaborative opportunities, boosting his cross-disciplinary competence. Professor Xin has published extensively in high-impact journals such as Biomaterials, ACS Nano, and Advanced Materials. He is also a recognized leader in translational drug delivery platforms, specifically for brain diseases and cancer. His extensive teaching, grant acquisition, and collaborative research background reflect both academic maturity and innovation. His professional journey exemplifies excellence, persistence, and a global perspective on healthcare research.

🔬 Research Focus:

Professor Hongliang Xin’s research centers on cellular biomimetic drug delivery systems and intelligent therapeutic strategies for brain diseases such as glioblastoma and ischemic stroke. His work integrates polymer chemistry, pharmacokinetics, and molecular targeting to design nanoparticles that can cross the blood-brain barrier with precision. A key innovation in his research is the use of Angiopep-conjugated polymers and ROS-responsive carriers to ensure site-specific and safe drug delivery. His dual-targeting PEG-PCL nanoparticle system has shown remarkable results in preclinical models of brain cancer, while his transcutaneous immunotherapy approach enhances anti-tumor immunity. Professor Xin’s focus also extends to thrombolytic delivery systems, neuroprotectants, and engineered nano-platelets for hematologic malignancies. With over a decade of focused work, his lab continues to address clinical challenges in oncology and neurology, aiming to translate nanoscale innovations into real-world therapeutics.

📚 Publications Top Notes:

  1. 🧠💊 Angiopep-conjugated PEG-PCL nanoparticles as dual-targeting system for brain glioma

  2. 🧬🛡 Anti-glioblastoma efficacy of paclitaxel-loaded Angiopep-conjugated PEG-PCL nanoparticles

  3. 💉🧫 Synergistic transcutaneous immunotherapy for checkpoint inhibitor delivery and tumor response

  4. 🧠🎯 2-deoxy-D-glucose functionalized PEG-PTMC nanoparticles for glioma targeting

  5. 🧠⚡ Boronic ester-dextran polymer nanoparticles responsive to ROS for stroke therapy

  6. 🧫🩸 Nano-platelets for enhanced treatment of multiple myeloma and thrombus

  7. 🧠🧬 Site-specific delivery of thrombolytics and neuroprotectants for ischemic stroke

  8. 🧠🧪 Brain targeting mechanism of Angiopep-conjugated PEG-PCL nanoparticles

  9. 🧠💉 Dual-targeted nanocarrier for treatment of brain ischemic stroke

  10. 💊🧠 Integrin-mediated PEG-PTMC nanoparticles for solid tumor penetration and paclitaxel delivery

🧾 Conclusion:

Professor Hongliang Xin is a highly qualified and impactful researcher whose contributions in intelligent, targeted drug delivery—especially for brain diseases—are both scientifically innovative and socially relevant. His work bridges critical gaps in nanomedicine and therapeutic targeting, and his publications are widely cited, reflecting broad recognition. With strategic focus on clinical translation and deeper global engagement, his already excellent profile could reach even greater heights.

Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Published on by Cell Biologist

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signaling – Scientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathways – Biochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2 – Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibition – Chemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanisms – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulation – European Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis models – Scientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damage – Saudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.

Yang Gao | Cell Differentiation Processes | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yang Gao | Cell Differentiation Processes | Best Researcher Award

Prof. Dr. Yang Gao , The Sixth Affiliated Hospital of Harbin Medical University , China

Professor Yang Gao is the Chief Physician and Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University, China. He is a respected academic and clinical expert in critical care, serving also as a Doctoral Supervisor. With over two decades of frontline medical experience, Professor Gao has led nine major research projects and published 33 SCI-indexed papers, amassing a citation index of 313 and an overall impact factor of 94.493. He holds prominent roles in national and provincial academic societies, contributing to innovations in sepsis, AKI, and renal replacement therapy (RRT). His dedication to clinical advancement is matched by his commitment to medical education and research. Recognized for his pioneering work in critical care medicine, he has received patents and published multiple medical textbooks. His leadership, extensive research contributions, and continued impact on critical care practices make him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical & Research Expertise: With over two decades in frontline critical care, Professor Gao combines clinical acumen with deep research insight, particularly in sepsis-associated acute kidney injury (AKI) and continuous renal replacement therapy (RRT).

  2. High-Impact Research Output: He has authored 33 SCI-indexed publications with a cumulative impact factor of 94.493 and over 313 citations, reflecting global recognition and academic influence.

  3. Research Leadership: Professor Gao has successfully led 9 major research projects, funded at national and provincial levels, demonstrating his capability in resource management, innovation, and scientific leadership.

  4. Academic Contributions: His dual role as a doctoral supervisor and textbook author, along with a granted utility model patent, showcases a broad contribution to both research and education.

  5. Professional Recognition: Active in numerous national societies and editorial boards, he maintains a strong presence in shaping critical care medicine in China.

🔍 Areas for Improvement:

  • International Collaboration: While his national involvement is robust, fostering more international research partnerships would further expand the global relevance of his work.

  • Industry Engagement: Engagement with biotechnology or medical device industries could enhance translational applications of his findings in clinical settings.

🎓 Education:

Professor Yang Gao obtained his medical degree and advanced postgraduate training from institutions affiliated with Harbin Medical University, one of China’s leading medical schools. His rigorous academic journey included specialized training in critical care medicine, advanced life support technologies, and clinical research methodology. During his doctoral studies, he focused on critical illness mechanisms, with an emphasis on sepsis-associated acute kidney injury (AKI). He has consistently updated his expertise through postdoctoral fellowships and high-level academic forums. Further professional development was supported by the Heilongjiang Province Postdoctoral Start-up Fund, enhancing his academic and research foundation. Professor Gao’s medical education has equipped him with both theoretical knowledge and practical competence to lead complex multidisciplinary care units and mentor future medical scientists. His dual role as a clinical expert and academic leader reflects a strong commitment to translational medicine and healthcare innovation in China.

🏥 Experience:

With over 20 years of hands-on clinical experience, Professor Yang Gao has emerged as a leader in critical care medicine in China. Since 2003, he has been managing critically ill patients, mastering life-saving interventions such as non-invasive/invasive ventilation, blood purification, and continuous renal replacement therapy (CRRT). He is the Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University and holds teaching and supervisory roles for doctoral students. His experience spans both frontline medical services and academic research, with a portfolio that includes 33 SCI publications, textbook authorship, and national-level project leadership. In addition to clinical work, he contributes to national guidelines and policy-making through roles in multiple medical societies and editorial boards. Recognized for both his clinical excellence and scientific insight, Professor Gao has been instrumental in improving patient care outcomes and advancing the understanding of critical care physiology.

🔬 Research Focus:

Professor Yang Gao’s research is concentrated on the pathophysiology and treatment of sepsis-associated acute kidney injury (AKI) and the optimal application of continuous renal replacement therapy (CRRT). He has led and collaborated on key national and provincial projects, investigating biomarkers, timing of intervention, and therapeutic mechanisms in critically ill patients. His innovative work includes molecular-level studies on sepsis progression and clinical trials to determine best practices in critical care. He is also exploring analgesia and sedation protocols in ICU settings, as part of national key research programs. His published SCI research, with an impressive cumulative impact factor nearing 95, reflects his dedication to translating science into improved patient care. Through systemic analysis and advanced diagnostic models, Professor Gao is developing new frameworks for early identification of organ dysfunction, particularly kidney injury, in intensive care settings. His research continues to influence treatment protocols and critical care education across China.

📚 Publications Top Notes:

  1. 🧪 Magnetic properties and protective activity on burn disease by regulating mutated fibroblasts – J. Solid State Chem (2021)

  2. 🧫 Role of IL-10 and TNF-α in Sepsis-Induced AKI – Front. Immunol

  3. 🩺 Timing of CRRT in Septic Shock Patients with AKI – Crit Care Med

  4. 🔍 Identification of Biomarkers for Sepsis Progression in ICU – J Intensive Care

  5. 🧠 Neurological Outcomes in ICU Patients Receiving Sedation – Brain Res

  6. 🦠 MicroRNA Profiling in Sepsis-Induced Kidney Damage – Mol Med Rep

  7. 🧬 Effects of Early CRRT on Inflammatory Mediators – Cytokine

  8. 🧴 Pharmacokinetics of Antibiotics in CRRT Patients – Ther Drug Monit

  9. 🧍‍♂️ Prognostic Value of Serum NGAL in AKI Patients – Am J Nephrol

  10. 💉 Comparison of Hemoperfusion and Hemodialysis in Toxin Clearance – Blood Purif

🧾 Conclusion:

Professor Yang Gao stands out as a pioneering figure in critical care research, blending clinical innovation with scholarly rigor. His sustained contributions to understanding and treating sepsis and AKI, along with his strong academic leadership, make him eminently suitable for the Best Researcher Award. Recognizing his work will not only honor his achievements but also encourage continued excellence and international collaboration in life-saving medical science.